The content on this site is intended for healthcare professionals only
Prof Xavier Leleu speaks to ecancer about a discussion into anti-CD38 immunotherapy treatment that he participated in at the recent MyKE Myeloma 2021 meeting.
He explains that in recent years we have seen the success of the anti-CD38 immunotherapy agent daratumumab followed by another in isatuximab.
Prof Leleu discusses three different situations in which a sequence of daratumumab and isatuximab could be beneficial.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms
EHA 2024: Multiple myeloma roundup
Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line
